As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

The PANSS is currently the most established scale in patients with schizophrenia. For example in the high impact journal "Schizophrenia Bulletin" Kay's publication on the Positive and Negative ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

Arimoclomol是一款口服、潜在“first-in-class”的细胞热休克反应共诱导剂，开发用以治疗NPC。 该疗法曾获FDA授予孤儿药资格、快速通道资格、突破性疗法认定以及罕 ...

New safety data shows an absence of post-injection syndrome, a rare and serious side effect of long-acting olanzapine.

NBI-568 came up short in terms of PANSS reduction, with a 7.5pt placebo-adjusted reduction missing the double-digit target the Street wanted to see. Management remains optimistic about '568 ...

RVPH RECOVER Vocal Biomarker Data On September 4, 2024, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) held a k ey ...

Neurocrine Biosciences Inc.’s top-line phase II data, though billed as promising, wasn’t enough to please observers on Wall Street, who stacked the data in schizophrenia with NBI-1117568 (NBI-'568) ...

“While we are positive on the effect size demonstrated by NBI-‘568, we anticipate weakness given the placebo-normalized PANSS score improvement of 7.5 is notably below others in the space and ...

The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week ...